Roger Jelliffe MD1, Alan Schumitzky PhD1,2, David Bayard PhD1,3, Robert Leary1,4, PhD, Alison Thomson PhD5, Andreas Botnen, MS1, Maurice Khayat BS1, Michael Neely MD1 Optimal Stochastic Control Of Drug Dosage Regimens
|
Carlos Hoyo-Vadillo and Hector González M. Pharmacokinetic Model for Losartan Administered to Young Mexican Healthy Volunteers.
|
Amélie Marsot (1), Edith Ramain (2), Olivier Perus (2), Nicolas Simon (1) External validation of pharmacokinetic population model of alfentanil in obese patients.
|
A.H. Mohammadpour(1), S. Rezaee(2), S. Sadray(3), P. Ghaeli(4) Population pharmacokinetics of carbamazepine in Iranian epileptic and manic patients
|
Balaji M. Agoram, Rhys Jones & Piet H van der Graaf, A Physiologically-Based Mathematical Model to Predict Lung Retention and Inhaled Pharmacokinetics of Therapeutic Candidates
|
Hugh McDevitt (1), Goonaseelan Pillai (1), Kai Wu (1), Ramprasad Ramakrishna (1), Gerard JP Flesch (1), Georges Ette (1), Sreeni Devidas (2), Rajasekhar Thatavarti (2), Vincent Buchheit (1). Infrastructure development for building, maintaining and modeling indication- specific summary-level literature databases to support model based drug development.
|
Brenda CM de Winter(1), Ferdi Sombogaard(1), Reinier M van Hest(1), Teun van Gelder(1,2), Ron AA Mathot(1) Mechanism-based pharmacokinetic modelling of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients
|
R.R. Press(1,2), H.H. van Rossum(3), B.A. Ploeger(4,5), J. den Hartigh(1), J. van Pelt(3), H.-J. Guchelaar(1), J.W. de Fijter(2) and M. Danhof(4,5) Is Calcineurin Activity Useful as a Biomarker to Optimize Cyclosporine A Therapy in Renal Transplant Recipients?
|
Maurice J. Ahsman (1), Manon Hanekamp (2), Enno D. Wildschut (2), Dick Tibboel (2), Ron A.A. Mathot (1) Population Pharmacokinetics of Midazolam and Metabolites during Venoarterial Extracorporeal Membrane Oxygenation in Neonates
|
Hanna E Silber (1,3), Nicolas Frey (2), Mats O Karlsson (1) An integrated model for glucose-insulin regulation to describe oral glucose tolerance test data in healthy volunteers
|
T. Wajima (1, 2), G.K. Isbister (3, 4), S.B. Duffull (1) A comprehensive model for the coagulation network in humans
|
Dalia A. Vásquez-Bahena (1), Uzziel E. Salazar-Morales (1), Mario I. Ortiz (2), Gilberto Castañeda-Hernández (1) and Iñaki F. Trocóniz (3). Population Pharmacokinetic-pharmacodynamic modeling of the Analgesic Effects of Lumiracoxib, a selective inhibitor of the enzyme COX2 in the Rat
|
Johan E Wallin , Lena E Friberg , Mats O Karlsson Model Based Neutrophil Guided Dose Adaptation in Chemotherapy
|
H. Abou hammoud(1), N. Simon(2), S. Urien(3), B. Riou(4), P. Lechat(1), F. Aubrun (5) Population Kinetic Pharmacodynamic and Logistic Regression Analysis of Intravenous Morphine Titration in Immediate Postoperative Period
|
Lorea Bueno1, Dinesh P de Alwis2, Colin Miles2, Sophie Glatt2, and Iñaki F. Trocóniz1 Semi-Mechanistic Modelling of the Tumour Growth Inhibitory Effects of a New Anti-angiogenic Drug.
|
Dickinson GL, Jackson KJ Prediction of a Metabolic Drug-Drug Interaction in a Virtual Human Population using in vitro Enzyme Kinetic Information
|
Ivelina Gueorguieva, Kimberley Jackson, Steven A. Wrighton, Vikram P Sinha and Jenny Y. Chien Desipramine Population Pharmacokinetic Model and Designing CYP2D6 Drug-Drug Interaction Studies
|
Leonid Gibiansky (1), Ekaterina Gibiansky (2) Pharmacodynamic Modeling of Biologics with Target-Mediated Drug Disposition: TMDD Approximations, Relation to Indirect-Response Models, and Application to Population PK-PD Analyses
|
Shuying Yang, Pauline Lukey and Misba Beerahee Bayesian Adaptive Designs for Phase IIb Dose-ranging Study in Rheumatoid Arthritis (RA)
|
Bizzotto R (1), Zamuner S (2), De Nicolao G (3), Cobelli C (1), Gomeni R (2) Multinomial logistic functions in Markov-chain models for modelling sleep architecture after placebo administration
|
Celine Pitou, PharmD1; Inaki Troconiz, PhD2; Sophie Glatt, PhD3 Modelling of PK/Efficacy/Toxicity in rats to help design a First Human Dose for a cell cycle inhibitor X
|
Bojan Lalovic, Matt Hutmacher, Bill Frame, Raymond Miller Impact of Dosing Regimens on Dropout Across Pregabalin Trials in the Treatment of Generalized Anxiety Disorder: Model Refinements and External Validation
|
M. Frank (1), A. Kunz (2), G. Harms (2), C. Kloft (1) Population pharmacokinetic model development and evaluation after nevirapine administration to mothers and newborns
|
M. Scholz (1), N. Plock (1,2), C. Kloft (1) Optimal Design for the improvement of sampling schedules of microdialysis studies.
|
Srividya Neelakantan (1), Kevin Sweeney (1), Haiqing Dai (1), Steven G Terra (2), Thomas G Tensfeldt (1) Exposure-Response Analysis of a DPP-IV Inhibitor, PF-00734200 on HbA1c in Type 2 Diabetic Subjects on Stable Metformin Treatment
|
AK Hamberg (1)(4), JD Lindh (2), M Wadelius (1), A Rane (2) ML Dahl (1), EN Jonsson (3)(5) A longitudinal model describing the relationship between warfarin dose and INR response taking CYP2C9, VKORC1 and age into account
|
M. Neely (1,2,3), T. Rushing (4), A. Kovacs (3), R. Jelliffe (2), J. Hoffman (1) Voriconazole Population Pharmacokinetics and Pharmacodynamics in Children
|
K. Vučićević(1), B. Miljković(1), M. Pokrajac (1), M. Prostran (2), Ž. Martinović (3), R. Veličković (4), I. Grabnar(5) Effect of Valproic Acid Daily Dose on its Clearance in Adult Patients with Epilepsy – Population analysis of TDM data
|
F. Jonsson(1), A. Fleury(2), T. Lavé(2) A pharmacokinetic-pharmacodynamic model for ECG pattern changes in dog and monkey
|
Helene Karcher, Phil Lowe Harnessing clinical knowledge on ligand-targeting drug to develop a new compound targeting the associated receptor : an example of model-based biologics design in pre-clinical development
|
Helene Karcher (1), Ken Abrams (2), Alan Slade (2), Olivier Luttringer (1) Interpreting QT in a Patient Population After Surgical Intervention
|
Jianping Zhang, Daphne D. Williams, Katy P. Moore Use of Eltrombopag Exposure-Platelet Response Relationship for Dose Optimization in Patients with Chronic HCV-Infection with and without Interferon
|
J-S van der Walt [1], K Cohen [1], HM McIlleron [1], PJ Smith [1], G Maartens [1], MO Karlsson [2] Effect of rifampicin-based antitubercular therapy and cotrimoxazole on the population pharmacokinetics of stavudine (d4T) in HIV-1 infected patients
|
Alienor Berges, Bart Laurijssens, Chao Chen An Efficiency Comparison between Concentration-Response Analysis and Dose-Response Analysis through Simulation
|
Alexandre SOSTELLY (1, 2), Emilie HÉNIN (1), Benoit YOU (2), Pascal GIRARD (2), Mats O KARLSSON (1) Simultaneous modelling of PSA production in Prostatic Benign Hyperplasia (PBH) and prostatic adenocarcinoma patients treated by prostate surgery
|
A.-L. FLAUGERE(1), M. CARLES(2), E. RAMAIN (2), A. BOULAMERY-VELLY(1), N. SIMON(1) Population pharmacokinetics of imipenem bone concentrations in pigs
|
Hannah M Jones Use of PBPK modelling in drug discovery at Pfizer
|
I. Bondareva, O. Andreeva Population Pharmacokinetics of Carbamazepine and Estimation of Influencing Factors
|
Ekaterina Gibiansky (1), Jianping Zhang (2), Daphne Williams (3), Zhao Wang (1), Daniele Ouellet (2) Population Pharmacokinetics of Eltrombopag in Healthy Subjects and Patients with Chronic Idiopathic Thrombocytopenic Purpura
|
Elke H.J. Krekels(1,2), J.G. Coen van Hasselt (1), Dick Tibboel(2), Monique van Dijk(2), Sinno H.P. Simons(2), Caroline D. van der Marel(2), Richard A. van Lingen(3), Anne M. Lynn(4), Imti Choonara(5), Meindert Danhof(1), Catherijne A.J. Knibbe(1,2,6) Evaluation of morphine pharmacokinetic models in neonates and infants.
|
Stefanie Hennig, Lena E. Friberg, Mats O. Karlsson Characterizing time to conversion to sinus rhythm under digoxin and placebo in acute atrial fibrillation
|
A. Dubois (1), M. Lavielle (2), S. Gsteiger (3), E. Pigeolet (3) and F. Mentré (1) Extension of the SAEM algorithm and evaluation of Wald and likelihood ratio tests for interaction or bioequivalence studies
|
D. Renard, K. Wu, R. Wada, G. Flesch Using desirability indices for decision making in drug development
|
Jeroen Elassaiss-Schaap and Siem Heisterkamp Variability as constant coefficient of variation: Can we right two decades in error?
|
W. Krzyzanski (1), P. Kawczak (1), P. Wiczling (2), P. Lowe (3), E. Pigeolet (3), F. Ludicke (4), S. Balser (4). Receptor Mediated Disposition PK/PD Model of Filgrastim in Healthy Adults following Intravenous and Subcutaneous Administrations.
|
Anne Chain (1), Jeanne Dieleman (2), Meindert Danhof (1), Miriam CJM Sturkenboom (2, 3), Oscar Della Pasqua (1, 4) Not-In-Trial Simulation: Predicting cardiovascular risk from clinical trial data
|
Gregory Pinault, Aurelie Gautier, Goonaseelan Pillai, Jean-Louis Steimer, Vincent Buchheit Quality, Efficiency and Industrialisation Initiatives during the evolution of a dedicated SAS Programming Group
|
Rocío Lledó-García, Stefanie Hennig, Joakim Nyberg, Andrew C. Hooker & Mats O. Karlsson Seeking ethically attractive dose-finding designs for narrow therapeutic index drugs
|
Pinky Dua, Alienor Berges, Chao Chen, Roberto Gomeni ADAS-Cog Placebo Modelling in Alzheimer’s Disease
|
P. L. S. Chan (1), P. Jacqmin (2), M. Lavielle (3), L. McFadyen (1), B. Weatherley (1) Population Pharmacokinetic-Pharmacodynamic-Viral Dynamics Modelling of Maraviroc Monotherapy Data Using MONOLIX
|
Mike K Smith (1), Richard Pugh (2), Romain Francois (2) MSToolkit – An R library for simulating and evaluating clinical trial designs and scenarios
|
Paul G. Baverel, Radojka M. Savic, Mats O. Karlsson Two PsN Bootstrapping Routines for Obtaining Uncertainty Measurement around the Nonparametric Distribution Obtained in NONMEM VI
|
Emma K. Hansson(1), Brett Houk(2), Michael Amantea(2), Peter Milligan(2), Mats O. Karlsson(1), Lena E. Friberg(1) Pharmacokinetic-Pharmacodynamic Modeling of the Angiogenic Factors VEGF, sVEGFR-2, sVEGFR-3 and sKIT following Sunitinib Treatment in GIST
|
Valerii V. Fedorov, Sergei L. Leonov Estimation of Population Pharmacokinetic Measures and Selection of Sampling Times
|
S. Goutelle (1,2), L. Bourguignon (1,2), N. Bleyzac (1,3), P. Maire (1,2), R.W. Jelliffe (4) Performing Monte Carlo Simulation Based on Nonparametric Pharmacokinetic Parameter Distributions: Evaluation of Various Methods Applied to a Paediatric Population Study on Busulfan
|
Leonid Gibiansky (1), Tarundeep Kakkar (2), Peiming Ma (2) Population Pharmacokinetics of AMG 317, a Fully Human Anti-IL-4Rα IgG2 Monoclonal Antibody Evaluated in Healthy and Asthmatic Subjects
|
M. Lavielle (1), A. Samson (2), A.K. Fermin (3) and F. Mentré (4) Parameter estimation of long-term HIV dynamic model in the COPHAR2 – ANRS 111 trial using MONOLIX
|
E. Pigeolet (1), P. Wiczling (3), P. Lowe (1), S. Balser (2), A. Berghout (2) and W. Krzyzanski (4) Artefactual inflation of pharmacokinetic difference between two Granulocyte Colony Stimulating Factor (G-CSF) drug products by non compartmental analysis.
|
C. Castelain (1), A. Dalis (1), X. Deflorenne (1), M. Destrée (1), B. Lacroix (2), L. Sargentini-Maier (2) Implementation of a NONMEM cluster and add-ons within UCB
|
Jonathan Wagg and Michelle Green Estimation of cortical amyloid beta turnover rates
|
C Dansirikul1, A Staab1, L Salin2, S Haertter1, and T Lehr1 Population pharmacokinetic analysis of pramipexole extended-release formulation in Parkinson’s Disease (PD) patients
|
C Le Guellec (1), N Simon (2), D.Garot (3), R. Respaud (1), P Lanotte (4), H. Blasco (1), PF Dequin (3). Population pharmacokinetics of Ceftriaxone in intensive care unit (ICU) adult patients
|
N. Snelder (2), T. van Steeg (2), B. Ploeger (2), N. Attkins (1), P. van der Graaf (1) Safety pharmacology screening using a standardized population pharmacokinetic pharmacodynamic modelling approach
|
N. Snelder (2), C. Diack (2), N. Benson (1), B. Ploeger (2), P. van der Graaf (1) A proposal for implementation of the Markov property into a continuous time transition state model in NONMEM
|
Ann K. Miller (1), Mita M. Thapar (2), Siobhan C. Hayes (2), Colm Farrell (2), Bela R. Patel (1), Duane A. Boyle (1) Population pharmacokinetics of artesunate and dihydroartesunate in adults and children following administration of a fixed dose combination formulation of chlorproguanil-dapsone-artesunate
|
Laurent Nguyen, Aurelie Petain and Christian Puozzo Validation of a neutropenia PK/PD model built from intravenous vinflunine and its application to design phase I trials with oral vinflunine
|
James Yates, Rebecca Watson and Jason Cheung Validation of in vivo Mouse PK Assay by Mixed Effects Modelling: Estimation of between-study variability.
|
Ludivine Fronton(1), Benoit You(1,2), Marie Pollet-Villard(3), Gilles Freyer(1,2), Michel Tod(1), Olivier Colomban(1), Francois Golfier(3), Pascal Girard(1) Population model of Human Chorionic Gonadotropin to predict resistance in low risk gestational trophoblastic neoplasia patients
|
Klas J. Petersson(1), An M. Vermeulen(2), Lena E. Friberg(1) Could prolactin levels be a more informative predictor for clinical effect of D2-receptor antagonists than drug concentrations in the treatment of schizophrenia?
|
Siobhan Hayes (1), Daniele Ouellet (2), Jianping Zhang (2), Mary Wire (2), Ekaterina Gibiansky (1) Population PK/PD Modeling of Eltrombopag in ITP Patients and Optimization of Response-Guided Dosing
|
I. Ince(1,2), S.N. de Wildt(1), M.Y.M. Peeters(3), N.J. Vet(1), D. Tibboel(1), M. Danhof(2), C.A. Knibbe(1,2,3) Population PK modeling of Midazolam in Children; The effect of age versus other covariates
|
Richard Nixon Using short-term evidence to predict six-month outcomes in clinical trials of signs and symptoms in rheumatoid arthritis
|
M. Fontanilles(1), F. Pilleul(2), O. Colomban(1), B. Tranchand(1,5), A.M. Schott(3), J.A. Chayvialle(4), M. Tod(1) Modelization of bevacizumab effect on tumour perfusion assessed by Dynamic Contrast Enhanced Ultrasonography
|
Angelica L. Quartino (1), Lena E. Friberg (1), Sharon D. Baker (2) and Mats O. Karlsson (1) A semi-mechanistic myelosuppression model of docetaxel treatment in liver impaired patients
|
M.A. Boroujerdi (1), C. van Kesteren (1), A. Facius (2), M. Danhof (1), O.E. Della Pasqua (1,3) A turnover longitudinal model for the analysis of FEV1 changes in COPD
|
C. Ambery(1), M. Beerahee(1) Population PK-PD Modelling of Wheal and Flare Area in a First-Time-in-Human Study
|
S.Kulikov New parametric model for survival fitting
|
M.N. Trame (1), I.H. Bartelink (2), J. Boos (3), J.J. Boelens (2), G. Hempel (1,3) Population Pharmacokinetics of Dimethylacetamide in Children During Once-daily and Standard IV Busulfan Administration
|
Thaddeus Grasela* (1), Jill Fiedler-Kelly (1), Darcy Hitchcock (1) Improving the Efficiency and Ensuring the Quality of Data Assembly for Pharmacometric Analysis
|
Andreas Lindauer (1), Friederike Kanefendt (1), Cathleen Krambeer (1), Paola di Gion (2), Martina Kinzig (3), Fritz Sörgel (3), Uwe Fuhr (2), Ulrich Jaehde (1) Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib in Healthy Volunteers
|
C. Steven Ernest II(1,2), Andrew Hooker(1) and Mats O. Karlsson(1) Improved parameter estimation and design optimization for In Vitro ligand binding experiments
|
C. Becker(1), S. Willmann (1), T. Eissing (1), R. Burghaus (2), J. Lippert(1), G. Ahr(2), H. Stass(2) Whole-Body Physiologically-Based Pharmacokinetic (WB-PBPK) Modeling of Moxifloxacin (MFX) to Support a Translational Approach in Pediatric Study Design
|
D.S. Bordin, T.S. Kozhurina, S.Yu. Silvestrova, V.N. Drozdov, E.R. Valitova, A.A. Masharova, A.V. Petrakov Relating Pharmacokinetics and Pharmacodynamics of Proton Pomp Inhibitors (PPIs) to Clinical Performance in Patients with Gastroesophageal Reflux Disease (GERD)
|
Stefanie Hennig, Andrew C. Hooker, Joackim Nyberg Optimal design for models with semi-parametric distributions
|
Ramusovic S (1), Willmann S (2), Läer S (1) A physiologically based pharmacodynamic model of the Renin-Angiotensin-Aldosterone-System
|
Vivek Dua Initial Estimates for Parameter Estimation
|
G. Kersting (1,2), S. Willmann (3), G. Würthwein (2), J. Lippert (3) , J. Boos (2), G. Hempel (1,2) Physiologically-Based Pharmacokinetic (PBPK) Model for High- and Low Dose Etoposide: From Adults to Children
|
Rujia Xie1, Rosalin Arends2, Stephen Olson2 , and Scott Marshall1 Population Pharmacokinetic/Pharmacodynamic (PK/PD) Analysis of the Effect of Tanezumab on Overall Daily Pain Score Data in Adults with Moderate-to-Severe Pain due to Osteoarthritis of the Knee
|
Guangli Ma1, Bo L Olsson2, Johan Rosenborg2, Mats O. Karlsson1 Quantifying Lung Function Progression in Asthma
|
Elba Romero1, Josep-María Cendrós 2, Concepción Peraire2, Rosendo Obach2, and Iñaki F. Trocóniz.1 Impact of pharmacokinetic information reported as being below limit of quantification on the prediction of important response endpoints.
|
C. Csajka (1,4), A. Pascual (2) , S. Bolay (2), J. Bille (3), T. Calandra (2), O. Marchetti (2), T. Buclin (1) Population pharmacokinetics of voriconazole in patients with invasive mycoses
|
Andreas Kuttler (1), Thomas Dimke (1), Ramprasad Ramakrishna (2), Gabriel Helmlinger (2), Anne Ruehl (2), Marie-Laure Rouzade-Dominguez(2), Gervais Tougas (2), Mark Fox (3), Werner Schwizer (3) A 3D mechanical model of the gastric esophageal junction: model-based assessment of muscle stretch tension in the gastric smooth muscle with emphasis to reflux disease
|
Patanjali Ravva (1), Karthik Venkatakrishnan (2), Thomas G Tensfeldt (1), Carol Cronenberger (3) and John D Obourn (4) Population Pharmacokinetic-Pharmacodynamic Analysis of Weight Loss Efficacy of CP-945,598 in Adult Obese Subjects
|
Navarro-Fontestad C. (1), Fernandez-Teruel C. (2), Gonzalez-Alvarez . (3), Garcia-Arieta A. (4), Bermejo M. (3), Casabo VG. (1). Bioequivalence Trials Simulation to Select the Best Analyte for Drugs with Presystemic Intestinal and Hepatic Metabolism.
|
K. Bondareva External Validation of the Population Models for Carbamazepine Pharmacokinetics and the Individualizing Carbamazepine Dosage Regimen Procedure
|
Nicolás J (1), Oltra D (2), Navarro-Fontestad C (2), Nicolás N (3), Ramírez F (4), Alós M (5), Casabo VG (2) Population pharmacokinetics of Ropivacaine and Bupivacaine after loco-regional administration as anesthetic in hip or knee replacement surgery.
|
M.Guery (1), G.Herbin (1), C.Pobel (1), E.Kiep (1), C.Donamaria (2) Data mining analysis of survival data in cancer of pancreas : first exploratory step for identification and validation of explicative variables
|
M. Neve (1), L. Iavarone (1), M. Petrone (1), R. Gomeni (1) Assessment of NONMEM and WinBUGS performances when estimating power and sigmoid Emax models
|
Maria C. Kjellsson(1), Steven Kern(1,2), Robert Sauermann(3), Veronique Dartois (4), Goonaseelan (Colin) Pillai(1) Modeling the permeability of Fosfomycin into Abscess Fluid
|
S. Saleh(1), H. Staß(1), G. Ahr(1), R. Burghaus(1) Matching PBPK and NONMEM pharmacokinetics descriptions to understand and extrapolate - case study ciprofloxacin
|
HJ Blussé van Oud-Alblas (1), MYM Peeters (3), MJE Brill (4), CAJ Knibbe (2,3,4), J. Klein (1), D Tibboel (2), F. Weber (1) The pharmacodynamics of isoflurane in children using Bispectral index and composite auditory evoked potentials
|
Joseph F Standing (1), Marie Sandström (2), Tommy Andersson (2), Kerstin Röhss (2), Mats O Karlsson (1) Population Pharmacokinetic Modelling of Esomeprazole Nonlinearity
|
Monica Simeoni, Jonathan Bullman, Chao Chen Prediction of remifentanil metabolic ratio using sparse data collected during non-steady-state infusion with rapidly changing rate
|
W Smythe, H McIlleron, P Smith and USH Simonsson Mechanistic pharmacokinetic enzyme model for the characterisation of rifampicin pharmacokinetics in South African pulmonary TB infected adults
|
I. Locatelli (1), B. Perissutti (2), D Voinovich (2), A. Mrhar (1), I. Grabnar (1) Population Pharmacokinetic Analysis of Silymarin Bioavailability in Rats
|
Ted Grasela, Julie Passarell, Elizabeth Ludwig, Jill Fiedler-Kelly Modeling and Simulation Approach to Pediatric Drug Development
|
Ines Paule (1), Hind Sassi (2), Anoosha Habibi (3), Dora Bachir (3), Frédéric Galactéros (3), Pascal Girard (1), Anne Hulin (2), Michel Tod (1, 4) Population Pharmacokinetics and Pharmacodynamics of Hydroxyurea in Sickle Cell Anemia Patients, In Silico Comparison of Two Dosing Regimens
|
Wang, X (1), Anak O (1), Saro J (1), Cramer J (1), Shi M (1), Zhou W (1), Angevin E (2), Escudier B (2), Schran H (1) Population PK modeling and simulation to select a dosing schedule in Phase II trials for a novel TKI agent with time-dependent and nonlinear PK
|
Brigitte D. Lacroix(1,2), Mark Lovern(1), Armel Stockis(1), Maria Laura Sargentini-Maier(1), Mats O. Karlsson(2) and Lena E. Friberg(2) Exposure-Response Modeling of the ACR50 Score in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol.
|
Ashley Strougo(1,2); Walter Krauwinkel(1); Meindert Danhof(2); Jan Freijer(1) Mechanism-based pharmacokinetic modelling to describe the effect of protein binding on the pharmacokinetics of solifenacin
|
Marcus A. Björnsson (1,3), Åke Norberg (2), Sigridur Kalman (2), Mats O. Karlsson (3), Ulrika S.H. Simonsson (3) A two-compartment effect site model describes the Bispectral Index Score (BIS) after administration of propofol
|
S. Rezaee(1), T. Safarnavadeh(2), H. Khalili(2), S. Dashti(2), K. Daneshjoo(3), S. Sadray(4) Population Pharmacokinetics of Vancomycin in Iranian Paediatric Patients
|
Stacey Tannenbaum[1], Abhijit Chakraborty[1], Christiane Rordorf[2], Aurélie Gautier[2] & Philip Lowe[2] Pharmacokinetics of canakinumab and pharmacodynamics of IL-1β binding in patients with cryopyrin associated periodic fever syndromes
|
Viglinskaya A.O., Kolyvanov G.B., Mesonzhnik N.V., Baranov P.A., Litvin A.A., Zherdev V.P., Rodchenkov G.M. A physiology-based pharmacokinetic model describing the disposition of a novel selective anxiolytic drug afobazole and its metabolites in rats.
|
Stacey Tannenbaum[2], Aurelie Gautier[1] & Philip Lowe[1] Relationship between omalizumab pharmacokinetics and IgE pharmacodynamics in adult and pediatric patients with moderate to severe persistent allergic (IgE-mediated) asthma
|
Philip Lowe, Aurelie Gautier On the ability to predict free ligand suppression when free ligand assays are not available or impossible
|
Ramesh Sarangapani(1), Anna Georgieva(1), Ramprasad (Prasad) Ramakrishna(1), Gabriel Helmlinger(1), Donald Stanski(1), Arthur Lo(2), Manoj Rodrigo(2), Jennifer Beh(2) , Stuart Friedman(2) , Kortney Leabourne(2), Hector De Leon(2), Jeff Trimmer(2) Introducing the renin-angiotensin-aldosterone (RAAS) hypertension platform: an in-silico approach to evaluating efficacy of RAAS modulating drugs on blood-pressure control and end-organ protection
|
Philip Lowe[1], Stacey Tannenbaum[2], Aurelie Gautier[1] Omalizumab (Xolair) may normalise IgE production rate in patients with moderate-to-severe atopic asthma
|
Chao Chen (1), Jonathan Bullman (1), John Messenheimer (2) Concentration-Response Modelling of Adjunctive Lamotrigine Extended-Release for Primary Generalised Tonic-Clonic Seizures
|
D. Santos Buelga (1), E. López (2), S. Cabrera (3), R. López (4), E. Ribera (5), A. Domínguez-Gil (1,2), M.J. García (1). Population Pharmacokinetics of Lopinavir (Kaletra) in HIV-Infected Patients
|
Emilie HÉNIN, Martin BERGSTRAND, Mats O. KARLSSON Tablet position in gastrointestinal tract derived from drug release measurements and plasma concentrations
|
S.Y. Amy Cheung (1), Malcolm Rowland (2), Leon Aarons (2), Trudy Rodgers (1), Iva Gueorguieva (3) Development of a closed loop whole body (WB) physiologically based pharmacokinetic model (PBPK) of beta-blockers in the rat
|
Patanjali Ravva (1), Jonathan French (1), Sarah Dubrava (2) and Hélène M Faessel (3) Enhanced Clinical Trial Design of a Proof-of-Concept Study via Bayesian simulation analyses
|
Martin Bergstrand, Andrew C. Hooker, Mats O Karlsson Visual Predictive Checks for Censored and Categorical data
|
ÅM Johansson (1), N Mayne (2), S Hennig (1), M Perisoglou (2), J Whelan (2), MO Karlsson (1) , JF Standing (1) Pharmacokinetics of high-dose methotrexate in adults and children
|
C. Gérard (1), N. Bleyzac (2), P. Girard (1), B. Tranchand (1), G. Freyer (1), Y. Bertrand (2), M. Tod (1). Influence of cyclosporin infusion duration on efficacy in paediatric bone marrow transplantation: analysis by a PBPK model
|
C. Gérard (1), N. Bleyzac (2), P. Girard (1), B. Tranchand (1), G. Freyer (1), Y. Bertrand (2), M. Tod (1). Link between cyclosporin exposure in tissues and graft versus host disease in paediatric bone marrow transplantation: analysis by a PBPK model
|
Jeroen Diepstraten (1), Simone van Kralingen (2), Mariska Y.M. Peeters (1), Eric P.A. van Dongen (2), Bert van Ramshorst (3), Vera H.M. Deneer (1), Meindert Danhof (4) and Catherijne A.J. Knibbe(1,4) Population pharmacokinetics and pharmacodynamics of Propofol in morbidly obese patients
|
A. Russu (1), G. De Nicolao (1), I. Poggesi (2), R. Gomeni (2) Dose escalation studies: a comparison among Bayesian models
|
Damien Cronier (2), Lawrence Gelbert(1), Graham Wishart (2), Alfonso De Dios (1) A fully integrated PK/IVTI/IVE model in mouse to help design the FHD trial for a cell cycle inhibitor X
|
Varun Goel (1), Timothy E Hanson (2), Brian Corrigan (3), Raymond Miller (3), Richard C Brundage (1) A Bayesian Multivariate Model for Repeated Measures of Correlated Data
|
I. Grabnar (1), T. Trdan (1), P. Bohanec Grabar (2), B. Rozman (3), D. Logar (3), M. Tomsic (3), D. Suput (3), L. Peterlin Masic (1), V. Dolzan (2), A. Mrhar (1) Population Pharmacokinetics of the Active Metabolite of Leflunomide in Patients with Rheumatoid Arthritis
|
Anton Korobeynikov Comparison of Parameter Estimates for One Special Model of Survival Curves for Sample with Interval Censoring
|
A. Mohamed (1), E.I. Nielsen (1), O. Cars(2) and L.E. Friberg(1). Pharmacokinetic/Pharmacodynamic Modeling of Adaptive Resistance of Gentamicin
|
Flora Tshinanu Musuamba (1), Michel Mourad (2), Vincent Haufroid (3), Roger K. Verbeeck (1) and Pierre Wallemacq (3). Time of Drug Administration, Genetic Polymorphism and Analytical Method Influence Tacrolimus Pharmacokinetics: A Population Pharmacokinetic Approach
|
C. van Kesteren1, M.A. Boroujerdi1, A. Roy1, A. Facius2, M. Danhof1, O.E. Della Pasqua1,3 Prediction of drug effects using a longitudinal turnover model for FEV1 in patients with chronic obstructive pulmonary disease (COPD).
|
P Välitalo[1], E. Kumpulainen[1], M. Laisalmi[2], M. Lehtonen[1], A. Hooker[3], V-P. Ranta[1], H. Kokki[1,2] CSF and Plasma Pharmacokinetics of Flurbiprofen in Children
|
Bart Laurijssens Integrated analysis of Human PET data across multiple brain regions and receptors to make inferences from limited data.
|
Massimo Cella(1), Frank Kloprogge(1), Meindert Danhof(1) and Oscar Della Pasqua(1,2) Scaling of fixed-dose combinations in children
|
N.H. Prins (1), A. Cleton (2), M.O. Magnusson (2) , P. Johnson (2), A. Heatherington (2) Characterization of the population pharmacokinetics of UK-369,003 using a semi-mechanistic model
|
N.H. Prins (1), F. Jonsson (1), S. Haughie (2), P. Johnson (2), S.W. Martin (2) Comparison of a maximum likelihood versus a full bayesian method to jointly model individual with summary level data
|
N.H. Prins (1), M. Green (1), S. Haughie (2), P. Johnson (2), S. W. Martin (2) Use of model based meta-analysis combining patient-level with summary-level data using multilevel random effects to provide a quantitative assessment of the clinical efficacy (IPSS) profile and competitive positioning of a PDE5 inhibitor (UK369,003) for the treatment of benign prostatic hyperplasia (BPH).
|
Caroline Bazzoli , Sylvie Retout , France Mentré Prediction of power of test of discrete covariates in population analyses and influence of design: application to gender effect in joint pharmacokinetic models of nucleoside analogs and their active metabolites
|
Elodie Plan and Mats O. Karlsson New models for handling correlated underdispersed Likert pain scores
|
Elodie Plan, Yang Sun, Mats O. Karlsson Eleven ordered categories data: which modelling options?
|
Jonathan L. French (1), Neal Thomas (2), Sriram Krishnaswami (3), Gary Chan (4) Safety monitoring of a kidney transplant study using a Bayesian time-to-event model
|
KT. Baron, AK. Birnbaum, JC. Cloyd, J. St. Peter, and RC. Brundage Evaluation of Assumptions in the Clinical Use of the Cockcroft-Gault Equation
|
Massimo Cella (1), Frank L. Kloprogge(1), Meindert Danhof (1) and Oscar Della Pasqua (1,2) Comparative analysis of scaling methods for dose selection in paediatric indications
|
A. Martin-Suarez (1), D. Santos Buelga (1), E. Lopez (2), S. Cabrera (3), R. Lopez (4), E. Ribera (5), A. Dominguez-Gil (1,2), M.J. Garcia (1). Population pharmacokinetic model for Ritonavir (RTV) in HIV-infected patients treated with Lopinavir (LPV)/RTV (KaletraTM)
|
Paolo Denti (1), Alessandra Bertoldo (1), Paolo Vicini (2,3), Claudio Cobelli (1) Covariate Selection for the IVGTT Minimal Model of Glucose Disappearance
|
Martin Bergstrand (1), Sandra Visser (2), Catharina Alm (1), Ahmad Al-Saffar (3), Mats O Karlsson (1) Semi-mechanistic PK/PD modeling of Paracetamol and Sulfapyridine to characterize effects on gastric emptying and small intestinal transit
|
C.Pobel(1), M.Guery(1), G.Herbin(1), E.Kiep(1), C.Donamaria(2) Time to event models of survival in cancer of pancreas : confirmation of explanatory variables pre-selected by bootstrap analysis.
|
Emmanuelle Comets (1), Julie Antic (2), Rada Savic (1,3) A bibliographic review of non-parametric methods and their application
|
Paolo Denti (1), David Salinger (2,3), Paolo Vicini (2,4), Gianna Maria Toffolo (1), Claudio Cobelli (1) A NonLinear Mixed-Effects Approach to the Estimation of the Glucose Disposition Index
|
Jason H. Williams (1), Bhuvaneswari Jayaraman (1), Richard S. Finkel (2), Jeffrey S. Barrett (1) Bayesian Network Approach to Modeling Spinal Muscular Atrophy Populations
|
Daniel Moreno1, Sara Zalba1, Iñigo Navarro2, Conchita Tros1, Iñaki F. Trocóniz1, María J Garrido1 Pharmacokinetics and antitumor efficacy characterization of cisplatin-loaded PLGA nanoparticles in tumor-bearing mice.
|
Kayode Ogungbenro and Leon Aarons Sample Size/Power Calculations for Population Pharmacodynamic Experiments Involving Repeated Count Measurements
|
Musuamba F(1), Mourad M(2), Haufroid V(3), Wallemacq P(4), Verbeeck RK(1) Multivariate and Population Pharmacokinetic Analyses for Tacrolimus Area Under The Concentration-Time Curve Prediction in De Novo Renal Transplant Recipients
|
Andrew C. Hooker, Joakim Nyberg, Richard Höglund, Martin Bergstrand and Mats O. Karlsson Autocorrelation reduces sample time clustering in optimal design
|
H. Kramer1, A. Zandvliet1, R. Berg2, HJ Streefkerk4, P. Grobara3, P Peeters2, T Kerbusch1 Phase II dose selection for a hypothetical novel Direct Thrombin Inhibitor (DTI): an integrated approach using experimental and literature data.
|
L. Liefaard (1), D. Huntjens (2), A. Vermeulen (2) & H. Drenth (1) Modelling non-linear dose-dependent absorption profiles after oral prolonged release formulations
|
A. Edginton (1), C. Boscarino (2), P. Sidhu (1), W. Riggs (3), A. Szeitz (3), B. Cheung (2), H. Peng (2) Parameterization of a physiologically-based pharmacokinetic (PBPK) model for the simulation of ibuprofen pharmacokinetics under exercise and heat stress with validation from clinical data
|
KwangHo Park2, Bo-Hyung Kim1, MD, Namyi Gu1, MD, Kwang-hee Shin1, SoJeong Yi1, Tae-Eun Kim1, MD, Youngjo Lee2, PhD, In-Jin Jang1, MD, PhD Hierarchical-likelihood approach for nonlinear mixed-effect models
|
E. Rouits, M. Lovern, M.L. Sargentini-Maier Target-Mediated Drug Disposition Model to Describe Non-linear Kinetics of a Monoclonal Antibody
|
R. Ben-Av, V. Vainstein, E. Massuri, M. Shtilerman, Z. Agur Comprehensive Virtual Patient Platform Implemented For Anti-Angiogentic Drugs Development
|
S. Smirnov(1), A. Belashov(2), O. Demin(3) Application of pharmacokinetic-pharmacodynamic model to optimize dosing regime of antimicrobial drug Grammidin containing gramicidin S
|
P. Johnson (1), S. W. Martin (1), P. Milligan (1), A. Cleeton (2), A. Heatherington (2), A. Crossland (3), S. Haughie (3), J. Lamb (4), N. Tamimi (4) & N.H. Prins (5). Enhanced quantitative drug development (EQDD) of a selective PDE5 inhibitor for the treatment of benign prostatic hyperplasia (BPH)
|
Sven Mensing, Peter Nörtersheuser, Paul-Matthias Diderichsen Markov Modeling of Side Effect Related Dropout Rates by Introduction of Previous State Memory
|